FCPA enforcement report for Q3 2020
Harry Cassin
October 1, 2020
During the third calendar quarter, there were three corporate FCPA enforcement actions with penalties and disgorgement totaling about $182.7 million.… Continue Reading
Editors
Harry Cassin
Publisher and Editor
Andy Spalding
Senior Editor
Jessica Tillipman
Senior Editor
Bill Steinman
Senior Editor
Richard L. Cassin
Editor at Large
Elizabeth K. Spahn
Editor Emeritus
Cody Worthington
Contributing Editor
Julie DiMauro
Contributing Editor
Thomas Fox
Contributing Editor
Marc Alain Bohn
Contributing Editor
Bill Waite
Contributing Editor
Shruti J. Shah
Contributing Editor
Russell A. Stamets
Contributing Editor
Richard Bistrong
Contributing Editor
Eric Carlson
Contributing Editor
Posts Tagged: GSK
At Large: Why didn’t Novartis try to conceal its ongoing bribery?
Richard L. Cassin
July 23, 2020
I’m not defending what Novartis did or trying to find an excuse for the company. It violated the FCPA, and (along with a former subsidiary) paid nearly $347 million in penalties and disgorgement to resolve the offenses.… Continue Reading
It’s the right time to reassess China due diligence and compliance risks
Jenny Liang
July 8, 2020
China has been mentioned in more than 60 FCPA corporate enforcement actions, including eight in 2019 alone. So FCPA practitioners have long been wary of potential problems there. And yet, with serious recent developments potentially impacting trade and on-the-ground operations, now is a good time to reassess China compliance risks.… Continue Reading
Feds open new GSK China bribery investigation
Richard L. Cassin
February 8, 2018
GlaxoSmithKline said in a securities filing Wednesday that the DOJ and SEC asked for information about third-party advisers the company hired in China during a corruption investigation there.
GSK said it is also responding to requests from the SFO for more information about the third parties.… Continue Reading
Federal judge tosses China investigators’ RICO claims against GSK
Richard L. Cassin
October 2, 2017
A federal judge in Philadelphia Friday dismissed a civil complaint against UK-based GlaxoSmithKline brought by a British private investigator and his American wife and their China-based company.
Peter Humphrey and Yu Yingzeng, his wife and business partner, sued GSK a year ago.… Continue Reading
Elizabeth David-Barrett: Pharmas and the repeated failure of anti-bribery compliance
Elizabeth David-Barrett
April 20, 2017
Pharmaceuticals companies continue to fall foul of the FCPA and other anti-bribery laws, with a number of 2016 cases suggesting a vulnerability around marketing practices especially in the Asia-Pacific region. Why does a sector that is way ahead of the compliance game in so many ways keep getting caught out by anti-bribery laws?… Continue Reading
Tom Fox: Compliance in the Age of Mercantilism
Richard L. Cassin
February 23, 2017
What does the failure of the Kraft Heinz attempted hostile takeover of Unilever portend for the greater world of global anti-corruption enforcement specifically and compliance programs more generally?
As with most business issues during the new administration, things are in flux.… Continue Reading
Compliance Alert: Speaker fees are often toxic
Richard L. Cassin
January 4, 2017
Last month Forest Labs paid $38 million to settle allegations it paid doctors speaker fees for sometimes phony events so they would prescribe its drugs. It was the latest in a string of “speaker fee” cases.… Continue Reading
GSK pays SEC $20 million to settle China FCPA violations
Richard L. Cassin
September 30, 2016
The Securities and Exchange Commission said Friday UK-based pharma GlaxoSmithKline plc will pay a $20 million civil penalty to settle charges that it violated the Foreign Corrupt Practices Act when China-based subsidiaries spent millions of dollars on pay-to-prescribe schemes for several years to pump up sales.… Continue Reading
SFO Director Green: ‘There are plenty of foxes for the hounds to chase down’
Richard L. Cassin
November 25, 2014
Image courtesy of the SFOAt Pinsent Masons regulatory conference in London a few weeks ago, David Green, the chief of the UK Serious Fraud Office, talked about how many known frauds happen on his turf.… Continue Reading
Collective Action: A new approach to combat corruption (Part 7)
Brook Horowitz
October 28, 2014
In my prior post on Collective Action, I wrote about the importance of voluntary codes of conduct and concluded that in an era of weak regulation, corporate behaviour would have been significantly worse over the last decades without them.… Continue Reading
Job: Regional Specialist, Anti-Bribery & Corruption (GSK Singapore)
FCPA Jobs
June 4, 2014
Job Title: Regional Specialist, Anti-Bribery & Corruption
Employer: GlaxoSmithKline
Location: Singapore
Description
The ABAC Regional Specialists will understand their local market needs AND global ABAC issues to be able to feed information back to the ABAC Programme.… Continue Reading